New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

BEOVU (brolucizumab-dbll) injection, for intravitreal injection.

This specialty medication is authorized and manufactured internationally and is not registered or commercially distributed for retail sale in India. To verify patient eligibility, check international supply availability, or understand the regulatory logistics and documentation process: Call our Compliance Desk at 9891296838 or Email your Inquiry query@southdelhipharma.com.

BEOVU is a prescription medicine. BEOVU used for Neovascular (Wet) Age-Related Macular Degeneration (AMD).
INDICATIONS AND USAGE
BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD)
DOSAGE FORMS & STRENGTHS
Intravitreal injection: 6 mg/0.05 mL solution in a single-dose vial
Manufactured By: Novartis Pharmaceuticals Corporation
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “BEOVU ® (brolucizumab-dbll) injection” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

South Delhi Pharma is dedicated to facilitating access to critical, globally approved pharmaceutical therapies tailored to individual patient needs. Established in 1996, It has built a trusted reputation for assisting patients and healthcare institutions in navigating the regulatory frameworks required to securely source high-quality, international life-saving medications.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

This is an inquiry and facilitation request form. Submission does not constitute a sale, purchase order, or guarantee of medicine availability.

Description

Brolucizumab, sold under the trade name Beovu, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.

Related Products